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Highlights 
 
 First multimodal study of Katona therapy effects in PBD with long-term follow-up. 
 
 MRI and Katona evaluations allow early detection of cerebral palsy. 
 
 Katona therapy decreases the severity of motor disability in moderate-to-severe 
PBD. 
 
 Katona methodology for early detection can be applied in developing countries. 
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Abstract 
Aim: To determine the long-term efficacy of Katona therapy and early rehabilitation of 
infants with moderate-to-severe perinatal brain damage (PBD). 
Methods: Thirty-two participants were recruited (7-to-16 years) and divided into 3 groups: 
one Healthy group (n = 11), one group with PBD treated with Katona methodology from 2 
months of corrected age, and with long-term follow-up (n = 12), and one group with PBD 
but without treatment in the first year of life due to late diagnosis of PBD (n = 9). 
Neuropediatric evaluations, motor evoked potentials (MEPs) and magnetic resonance 
images (MRI) were made. The PBD groups were matched by severity and topography of 
lesion. 
Results: The patients treated with Katona had better motor performance when compared to 
patients without early treatment (Gross Motor Function Classification System levels; 75% 
of Katona group were classified in levels I and II and 78% of patients without early 
treatment were classified in levels III and IV). Furthermore, independent k-means cluster 
analyses of MRI, MEPs, and neuropediatric evaluations data were performed. Katona and 
non-treated early groups were classified in the same MRI cluster which is the expected for 
patient’s population with PBD. However, in MEPs and neuropediatric evaluations 
clustering, the 67% of Katona group were assigning into Healthy group showing the impact 
of Katona therapy over the patients treated with it. These results highlight the Katona 
therapy benefits in early rehabilitation of infants with moderate-to-severe PBD. 
Conclusions: Katona therapy and early rehabilitation have an important therapeutic effect 
in infants with moderate-to-severe PBD by decreasing the severity of motor disability in 
later stages of life. 
 
Keywords: perinatal brain damage; Katona therapy; early treatment; cerebral palsy; 
magnetic resonance imaging; motor evoked potentials. 
3 
 
Introduction 
 
Perinatal brain damage (PBD) is a heterogeneous neuropathological spectrum that affects 
the encephalic white and/or gray matter, which can occur between the 20th week of fetal 
life and the 28th postnatal day [1,2]. The etiology of PBD is multifactorial and different 
physiopathological mechanisms can be involved, such as hypoxia, ischemia, inflammation, 
and/or infections [3]. The incidence of neonatal encephalopathy is 8.5 per 1000 live births, 
in which 50 to 80% of cases have a hypoxic-ischemic history [4]. The diagnosis and 
severity of PBD can be determined by indirect approaches, for instance, clinical scoring 
systems, biomarkers, and biochemical assessment [5]. However, magnetic resonance 
imaging (MRI) is the most sensitive technique that allows delineating accurately the 
topography and severity of the brain lesion in the neonate and infant. In this sense, the 
topography and severity of PBD are decisive in the establishment of short and long-term 
sequelae, regardless of the neuropathological pattern [6]. PBD has a high variety of adverse 
outcomes depending on the topography and severity of brain lesion, ranging from mild 
abnormalities in infancy (e.g., delay in acquiring developmental milestones) to severe 
neurological sequelae that cause permanent disabilities. Cerebral palsy is the main cause of 
childhood motor disability and may be the most serious long-term sequela of moderate-to-
severe PBD [7]. However, as brain plasticity is greater in the developing than in the adult 
brain, timely diagnosis and early intervention are crucial. 
Katona neurohabilitation therapy is a therapeutic treatment that promotes the psychomotor 
and cognitive capabilities that neonates and infants have not yet developed [8,9]. Katona 
methodology is both diagnostic and therapeutic. Katona assessment and treatment are 
performed with maneuvers taking into account muscle tone, symmetry of the hemibodies, 
attention, auditory monitoring, eye tracking, and neurological signs of alarm. Katona 
assessment and therapy is also based on early integrated complex movements, triggered by 
different head positions, the “elementary neuromotor patterns”. These patterns are a series 
of complex and continuous movements (for a detailed review about Katona methodology 
see [10]).  
The main objective of this study is to establish the long-term efficacy of Katona therapy 
and early rehabilitation of infants with moderate-to-severe PBD. Our hypothesis, in this 
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study, is that infants with early diagnosis and treatment with Katona methodology, will 
have less severe neurological sequelae observed years after in childhood and adolescence, 
than infants with similar brain lesions but that did not receive early treatments. 
 
Material and methods 
The Ethics Committee of the Instituto de Neurobiología of the Universidad Nacional 
Autónoma de México (UNAM) approved this study, which also complies with the Ethical 
Principles for Medical Research Involving Human Subjects established by the Declaration 
of Helsinki. Informed written parental consent for participation in this study was obtained 
for all participants.  
Participants 
Thirty-two children and adolescents were recruited (14 females; range 7-to-16 years) for 
this study. Twenty-three of them were recruited from a total of 1,694 participants evaluated 
in the Unit for Neurodevelopmental Research at the UNAM during the period 2001 to 
2018. Three groups of children and adolescents were considered according to meet the 
following inclusion criteria: clinical history (e.g., multiple risk factors for PBD) and 
structural MRI compatible with moderate-to-severe PBD (or normal for Healthy group) 
when they started the treatment. i) Healthy group, with eleven right-handed participants (4 
females) between 8 and 11 years of age, all of them born at term (range 37-to-41 
gestational weeks), without neurologic or neuromotor illness, without risk factors for PBD, 
and with normal structural MRI and age-appropriate motor performance.  
ii) Katona group with twelve participants (6 females) between 7 and 16 years of age, nine 
patients with premature birth (range 27-to-36 gestational weeks), with multiple risk factors 
for PBD, MRI compatible with moderate-to-severe PBD, who have received Katona 
treatment and early rehabilitation since 2 months of corrected age (or before), and with a 7-
to-12 year follow-up in the Unit for Neurodevelopmental Research.  
iii) Group treated late (without Katona therapy) with nine patients (4 females) between 7 
and 16 years of age, all of them born prematurely (range 27-to-33 gestational weeks), with 
multiple risk factors for PBD, MRI compatible with moderate-to-severe PBD, but without 
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formal treatment in the first 12-to-18 months of life due to late diagnosis. All patients of 
this group were recruited in public health centers in Mexico with late diagnosis of PBD 
(≥12 months of corrected age) or spastic cerebral palsy diagnosis after 18-to-24 months of 
age. 
The PBD diagnosis was made in accordance with neuropediatric and MRI standards 
[5,6,11,12]. Group treated late was considered as a Control group since Katona therapy and 
early rehabilitation have proved to be useful [7,10,13,14]. Therefore, according to the 
declaration of Helsinki, no control clinical trials without treatment are permitted [15]. 
Participants with clinical history of traumatic brain injury, brain malformations, 
cardiovascular illness, and/or genetic pathology associated with brain abnormalities were 
excluded from this study.  
Evaluations 
Neuropediatric evaluations, specific motor performance tests, structural and quantitative 
MRI and motor evoked potentials (MEPs) by transcranial magnetic stimulation were made:  
a) Neuropediatric evaluation and motor performance tests: The clinical pediatric and 
neuropediatric examinations were made by physicians with wide experience in the field. 
The specific motor performance tests are: range of motion (ROM), muscle strength scale 
(Daniels scale), muscle tone (Ashworth scale), deep tendon reflex (DTR scale), manual 
ability (MACS; Manual Ability Classification System), and gross motor performance 
(GMFCS; Gross Motor Function Classification System). 
b) Structural magnetic resonance imaging (structural MRI): Brain MRI studies in infancy 
stage with early PBD detection aim were only obtained for the Katona group (only group 
with early diagnosis and longitudinal follow-up) and were acquired with a 1.0 Tesla MRI 
scanner (Philips Medical Systems, Best, Netherlands). Infant brains were scanned during 
natural sleep and participants used ear protection. Structural images included sagittal T1-
weighted and axial T2-weighted. Brain MRI studies for all participants in a range 7-to-16 
years (transversal analysis) were acquired with a 3.0 Tesla MRI scanner (General Electric 
Healthcare, Milwaukee, Wisconsin, US). All participants were awake and used ear 
protection. Structural images included: coronal 3D T1-weighted SPGR, coronal 3D T2-
weighted SE, axial T2-weighted FSE, 3D-TOF SPGR and diffusion tensor imaging. Time 
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acquisition for these five sequences was approximately 22 minutes. MRI parameters can be 
found in the supplementary material. Type of brain lesion: brain MRI studies were 
categorized according to neuroradiological patterns and perinatal clinical history, which 
correlates with the etiology, physiopathological mechanisms, and temporality of the lesion 
[6,11]. All neuropathological patterns detected in this sample indicate that the timing of the 
brain lesion occurred in the perinatal stage, according to Krägeloh-Mann and Horber 
classification [12]. Grade of severity of PBD: brain MRI studies in infancy stage were 
classified according to white and gray matter abnormality scales [16]. All patients showed 
moderate-to-severe white/gray matter abnormalities. Brain MRI studies of children and 
adolescents were classified according to severity for white matter injury in cerebral palsy 
[17]. The PBD groups were matched by severity and topography of lesion, namely, 
moderate-to-severe brain damage and injury in the territory of the corticospinal tract (motor 
cortex, superior corona radiata, posterior limb of internal capsule [PLIC], midbrain 
peduncle, basilar region of pons, and/or pyramid of medulla oblongata) occurred in 
perinatal stage. 
c) Quantitative magnetic resonance imaging (quantitative MRI): The volumes of the lateral 
ventricles and corpus callosum were obtained, as well as the areas of the PLIC. Manual 
segmentation of the corpus callosum and lateral ventricles was performed from coronal 3D 
T1-weighted SPGR sequence. Subsequently, estimates of the volumes and 3D 
reconstruction were made to verify the anatomy. The areas of the PLIC were obtained from 
diffusion RGB-color maps. Detailed segmentation methodology can be found in the 
supplementary material. 
d) Motor evoked potentials (MEPs): The MEPs are the result of averaging the compound 
muscle action potentials registered from the target muscle during transcranial magnetic 
stimulation of the corresponding primary motor (M1) cortex. The safety, ethical 
considerations, and application guidelines for the use of transcranial magnetic stimulation 
in clinical practice and research were carried out according to Rossi et al., 2009 [18]. Two 
surface AgCl electrodes were positioned over tibialis anterior in a belly-tendon classic 
montage and connected to an amplifier. Main characteristics of the amplifier are a gain of 
1000 dB; low-cut filters, 10 Hz; high filters, 3000 Hz. Electromyography was recorded 
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during MEPs acquisition (Neuronic Mexicana, S.A.; Mexico). Single-pulses of 5 Hz were 
delivered with double cone coil (Super-Rapid, Magstim Company, Whitland, United 
Kingdom) over M1 cortex of the tibialis anterior. The M1 cortex detection was realized 
using single pulses at 80 to 100% of maximum stimulator output and the subsequent record 
of compound motor action potential in contralateral target muscle at rest. The “hotspot” 
area was defined as the motor cortical area that triggers a compound motor action potential 
with greater amplitude, most consistent MEP by cortical mapping. Motor threshold was 
defined as minimum stimulus that produces a small compound motor action potential, equal 
to or slightly greater than 50 μV of amplitude in the resting muscles in at least half of 10 
consecutive trials [19]. MEPs of contralateral muscle to cortical stimulation were acquired 
at 120% of motor threshold or 100% of maximum stimulator output (in cases with motor 
threshold ≥85% of maximum stimulator output). Failure to obtain MEPs was considered as 
no response to 20-to-30 stimuli at maximum stimulator output [20]. 
e) Motor evoked potentials (MEPs) parameters: We acquired the motor conduction time 
parameters. Total and peripheral motor conduction times were defined as the time between 
the artifact of stimulation at the onset of compound muscle action potential and cortical and 
spinal stimulation, respectively. To obtain peripheral motor conduction time, spinal 
stimulation was performed by placing the focal coil at the level of the 5th lumbar vertebra. 
We calculate the central motor conduction time by subtracting peripheral motor conduction 
time from total motor conduction time. The conduction velocity was defined as the distance 
between two points (e.g., distance between vertex to tibialis anterior) divided by motor 
conduction time or latency (expressed in m/s). To calculate the conduction velocity 
parameters, were measured the distance from vertex to tibialis anterior (total conduction 
velocity), distance from vertex to spinal stimulation place (central conduction velocity) and 
distance from spinal stimulation place to tibialis anterior (peripheral conduction velocity). 
Katona methodology 
Katona methodology and preliminary results have been described in previous papers (see 
Harmony et al., 2016 [10], Harmony 2017 [14] and Garófalo-Gómez et al., 2019 [13]). 
However, this is the first study with a multimodal evaluation of long-term therapeutic 
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effects of Katona therapy and early rehabilitation in children and adolescents with 
moderate-to-severe PBD. 
Statistical analysis 
In this paper we use the well-known k-means algorithm since it has proved to be a reliable 
and simple tool for data mining [21]. Absence of normality and heteroscedasticity were 
demonstrated by Anderson-Darling test and Cumulative Distribution Function of Chi 
Square, respectively. Comparisons between groups (gestational age, weight at birth, Apgar 
score at five minutes, and age during assessments) were performed using Kruskal-Wallis 
test. A p-value <0.05 was considered statistically significant. 
 
Results 
The results of the comparisons of demographic variables between groups were as follows: 
gestational age, weight at birth, and 5-minute Apgar score were significantly different 
between Healthy group and Katona group. Gestational age and weight at birth were 
significantly different between Healthy group and Control group (p = 0.06 for 5-minute 
Apgar score comparison). No significant differences were found between Katona and 
Control groups when comparing gestational age (p = 0.09), weight at birth (p = 0.11), 5-
minute Apgar score (p = 0.67), and age during assessments (p = 0.75). Main demographic 
characteristics of groups are in Table 1. 
Neuropediatric evaluation and motor performance tests 
Table 2 shows the results of neuropediatric evaluations and specific motor performance 
tests of each participant. The patients treated early with Katona had better motor 
performance when compared to patients without early treatment. We found that 9 out of the 
12 (75%) children and adolescents treated with Katona could move without the help of 
assistive devices; these 9 children had levels I and II according to GMFCS, 2 children 
(17%) in level III, and 1 (8%) in level V. In contrast, 7 out of the 9 (78%) patients with 
PBD who did not receive early treatment were classified in levels III and IV of GMFCS 
and only 2 (22%) in levels I and II. Interestingly, two patients (17%) treated early with 
Katona therapy had a normal motor performance; conversely, neither patient in the late 
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treatment group had normal outcomes. The motor sequelae in the Katona group (12 patients 
= 100%) were hemiparesis in 6 (50%), triparesis in 2 (17%), monoparesis in 1 (8%), and 
quadriparesis in 1 (8%). Instead, the most severe motor sequelae were more frequent in the 
late treated group (9 patients = 100%); quadriparesis in 4 (45%), triparesis in 2 (22%), 
hemiparesis in 2 (22%), and paraparesis in 1 (11%). 
Magnetic resonance imaging (MRI) 
In relation to the MRI findings, Table 3 shows detailed characteristics of cerebral 
white/gray matter lesions, cerebellum abnormalities, grade of severity of injury, and 
neuropathological pattern. The most frequent pathologies in Katona group and Control 
group were: periventricular leukomalacia (PVL), arterial ischemic stroke, periventricular 
hemorrhagic infarction, and mixed patterns, as the PVL in concomitance with 
periventricular hemorrhagic infarction (Figure 1). Quantitative MRI also evidences 
structural alterations in both PBD groups with diminished volumes of the corpus callosum, 
increased volume of the lateral ventricles (Figure 2), as well as reduction of the PLIC area. 
The volumetric estimations of corpus callosum and lateral ventricles of all participants were 
made (n = 32). The areas measured of the PLIC of 31 participants were obtained, although 
it was not possible to obtain a diffusion RGB color map of the one patient in the Katona 
group. Quantitative MRI results can be found in Table 4. 
Motor evoked potentials (MEPs) 
The total conduction velocity and conduction velocity of the corticospinal tract were higher 
in the patients treated early with Katona methodology in relation to children and adolescent 
without Katona therapy (Control group). Furthermore, the MEPs parameters of the Katona 
group show similar values to Healthy group. In this sense, the mean of the total conduction 
velocity from the right hemisphere to left tibialis anterior of Katona group was 59 m/s vs 
52.8 m/s of the patients with late treatment (reference of Healthy group 63.9 m/s). The 
mean of the total conduction velocity from the left hemisphere to right tibialis anterior of 
Katona group was 57.9 m/s vs 49.7 m/s (Healthy group 64 m/s). Corticospinal tract velocity 
showed a similar trend (Healthy group > Katona group > Control group); right corticospinal 
velocity 52.2/46.7/39.9 m/s, and left corticospinal velocity 51.8/45.4/34.9 m/s. The mean 
motor threshold for right M1 cortex in Katona group was 74% of maximum stimulator 
10 
 
output vs 76% of the Control group (56% motor threshold of Healthy group) and mean 
motor threshold for left M1 cortex in Katona group was 74% vs 75% (59% on Healthy 
group). The MEPs of 30 participants were obtained, due to failure in obtaining MEPs for 
two patients in the group treated lately (no response to 20-to-30 stimuli). 
K-means cluster analysis 
The k-means algorithm for clustering data was applied to three different data bases: i) 
quantitative MRI (topography of lesion, corpus callosum volume, lateral ventricles 
volumes, and PLIC areas), ii) MEPs (motor threshold and conduction velocity parameters), 
and iii) neuropediatric evaluation/motor performance tests (ROM, Daniels scale, Ashworth 
scale, DTR scale and MACS). For classification purposes, the thirty-two children and 
adolescents recruited in this study were sorted into three classes defined by healthy 
participants (C1), patients that received Katona therapy (C2), and patients that no received 
Katona therapy (C3). Table 5 shows the confusion matrix for clustering results based on k-
means algorithm. 
 
Discussion 
This is the first multimodal study that provides evidence of long-term therapeutic effects of 
Katona therapy and early rehabilitation in infants with moderate-to-severe PDB. Katona 
and Control groups were matched by severity and topography of lesion, furthermore, no 
significant differences between these groups were found when comparing gestational age, 
weight at birth, and Apgar score at five minutes. Interestingly, both groups were classified 
in the same MRI cluster by k-means analysis, indicating statistically, and not only by MRI 
assessment, that patients of both groups have similar attributes. However, 66.6% of Katona 
group were misclassified as Healthy group for MEPs cluster and motor performance; both 
clusters with similar parameters between the groups showing the influence of Katona 
therapy over the patient group. Also note that for Control group the misclassification for 
MEPs and motor performance evaluation mainly remain on the patient section (Katona 
group and Control Group). This is not the first report that early intervention seems to 
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improve motor outcomes [10, 22, 23], however, it is the first report that such favorable 
results are associated with Katona therapy 10 years later. 
The improvement in motor performance of the Katona group may be explained by plastic 
changes of the undamaged or less affected motor cortex and/or corticospinal tract, with 
possible compensatory modifications in their development/ontogeny [24]. The critical 
developmental period of the motor system is around the first 12-to-18 months of life, 
mainly with degeneration or establishment of fast conducting ipsilateral fibers of 
corticospinal tracts [25]. We hypothesized that intense repetition of Katona maneuvers in 
very early stages of life produces a reorganization of the motor system in the brain. Another 
factor, as McCoy and his coworker reported, Katona therapy is also family centered 
[26,27]. This work has some limitations; maybe the most relevant is the absence of a 
control group with pre/post intervention studies, which for ethical considerations was 
discarded in the study design [15]. Other limitations are the sample size and the variability 
of treatments and/or amount of therapy applied to the group with late diagnosis of PBD. 
However, the results reached on this study, both subjective and objective, lays the 
foundation for a future study in a large sample evaluating the benefits of Katona therapy in 
the long-term evolution of children with PBD. 
 
Conclusions 
Early detection in infants younger than 2 months of corrected age with PBD or perinatal 
risk factors that are highly probable to result in a motor disability or cerebral palsy is 
possible with multidisciplinary evaluations, such as Katona methodology and MRI, even in 
developing countries such as Mexico. This system for very early PBD detection is viable 
and can be applied in many other countries. On the other hand, early treatment of these 
infants with Katona neurohabilitation procedure may prevent serious motor disabilities. 
Katona therapy and early rehabilitation have an important long-term therapeutic effect in 
moderate-to-severe PBD by decreasing the severity of motor disability in childhood and 
adolescence. 
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TABLE 1. Main Demographic Characteristics. 
Group Number of 
Participants  
  Gender   Gestational Age 
(weeks) 
  Weight at Birth 
(grams)  
  Age During Assessments 
(years) 
    F M   Mean SD   Mean SD   Mean SD 
Healthy 11   4 7   39.1 1.2   3,223.6 319.6   9.8 1.2 
Katona (early treatment) 12   6 6   34.1 3.7   2,203.3 880.8   10.7 3.1 
Control (late treatment) 9   4 5   30.8 2.3   1,485.5 398.3   11.1 2.9 
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TABLE 2. Neuropediatric Evaluations and Specific Motor Performance Tests 
Group Range of 
Motion 
(ROM) 
Daniels Scale Ashworth 
Scale 
Deep Tendon Reflex Manual 
Ability 
Classification 
System 
(MACS) 
GMFCS     
Palisano 
Scale 
 
Diagnosis 
Extremity: Upper Right / Upper Left / Lower Right / Lower Left Right / Left 
 
 
 
 
 
Healthy 
H1 C / C / C / C 4 / 4 / 4 / 4 0 / 0 / 0 / 0 ++ / ++ / ++ / ++ 1  /  1 N/A Normal 
H2 C / C / C / C 4 / 4 / 4 / 4 0 / 0 / 0 / 0 ++ / ++ / ++ / ++ 1  /  1 N/A Normal 
H3 C / C / C / C 4+ / 4+ / 4+ / 4+ 0 / 0 / 0 / 0 ++ / ++ / ++ / ++ 1  /  1 N/A Normal 
H4 C / C / C / C 4+ / 4+ / 4+ / 4+ 0 / 0 / 0 / 0 ++ / ++ / ++ / ++ 1  /  1 N/A Normal 
H5 C / C / C / C 4 / 4 / 4 / 4 0 / 0 / 0 / 0 ++ / ++ / ++ / ++ 1  /  1 N/A Normal 
H6 C / C / C / C 4 / 4 / 4 / 4 0 / 0 / 0 / 0 ++ / ++ / ++ / ++ 1  /  1 N/A Normal 
H7 C / C / C / C 4 / 4 / 4 / 4 0 / 0 / 0 / 0 ++ / ++ / ++ / ++ 1  /  1 N/A Normal 
H8 C / C / C / C 4 / 4 / 4 / 4 0 / 0 / 0 / 0 ++ / ++ / ++ / ++ 1  /  1 N/A Normal 
H9 C / C / C / C 4 / 4 / 4 / 4 0 / 0 / 0 / 0 ++ / ++ / ++ / ++ 1  /  1 N/A Normal 
H10 C / C / C / C 4 / 4 / 4 / 4 0 / 0 / 0 / 0 ++ / ++ / ++ / ++ 1  /  1 N/A Normal 
H11 C / C / C / C 4- / 4- / 4- / 4- 0 / 0 / 0 / 0 ++ / ++ / ++ / ++ 1  /  1 N/A Normal 
 
 
 
 
 
 
Katona 
(early 
treatment) 
K12 C / C / I / I 3 / 3 / 2 / 2 2 / 1 / 2 / 2 +++ / +++ / +++ / +++ 3  /  2 3 Triparesis (lower extremities 
and upper right limb 
affected) 
K13 C / I / C / I 4 / 3 / 4 / 3 0 / 2 / 0 / 2 ++ / +++ / ++ / +++ 1  /  3 2 Left hemiparesis 
K14 C / C / C / C 4 / 4 / 4 / 4 0 / 0 / 0 / 0 ++ / ++ / +++ / +++ 1  /  1 1 Normal 
K15 C / I / C / I 4 / 3 / 4 / 3 0 / 2 / 0 / 2 ++ / +++ / ++ / +++ 1  /  2 2 Left hemiparesis 
K16 C / C / C / C 4 / 3 / 4 / 3 0 / 0 / 0 / 0 ++ / +++ / ++ / +++ 1  /  2 1 Monoparesis of left upper 
limb 
K17 C / C / C / C 3 / 4 / 3 / 4 1+ / 0 / 1+ / 0 +++ / ++ / +++ / ++ 3  /  1 2 Right hemiparesis 
K18 C / C / C / C 4 / 4 / 4 / 4 0 / 0 / 0 / 0 ++ / ++ / ++ / ++ 1  /  1 1 Normal 
K19 C / C / C / C 3 / 4 / 3 / 4 0 / 0 / 1 / 0 +++ / ++ / ++ / ++ 2  /  1 1 Right hemiparesis 
K20 C / I / C / C 4 / 3 / 4 / 3 0 / 1+ / 0 / 0 ++ / +++ / ++ / +++ 1  /  2 1 Left hemiparesis 
K21 I / I / I / I 3 / 4 / 3 / 4 2 / 0 / 1+ / 0 +++ / ++ / +++ / ++ 3  /  1 1 Right hemiparesis 
K22 I / C / I / I 2 / 3 / 2 / 2 1+ / 0 / 2 / 1+ ++ / ++ / +++ / +++ Did not 
cooperate 
5 Triparesis (lower extremities 
and upper right limb 
affected) 
K23 I / I / I / I 2 / 2 / 1 / 1 1+ / 2 / 2 / 3 +++ / +++ / +++ / ++++ 4  /  3 3 Quadriparesis with 
predominance in left 
hemibody 
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Control 
(late 
treatment) 
L24 I / I / I / I 3 / 2 / 1 / 1 1+ / 2 / 3 / 4 ++ / +++ / +++ / +++ 2  /  3 4 Triparesis (lower extremities 
and upper left limb affected) 
L25 I / I / C / C 3 / 3 / 3 / 3 1 / 1+ / 2 / 2 + / +++ / + / +++ 2  /  3 3 Paraparesis 
L26 I / I / I / I 2 / 3 / 1 / 2 3 / 1+ / 4 / 2 +++ / +++ / +++ / +++ 4  /  3 4 Quadriparesis with 
predominance in right 
hemibody 
L27 C / C / I / I 3 / 3 / 3 / 3 0 / 0 / 0 / 1+ ++ / +++ / ++ / +++ 1  /  2 2 Left hemiparesis 
L28 C / C / I / I 3 / 3 / 2 / 3 1+ / 0 / 3 / 2 +++ / +++ / +++ / +++ 3  /  2 3 Quadriparesis with 
predominance in right 
hemibody 
L29 I / I / I / I 2 / 3 / 2 / 3 2 / 1+ / 2 / 1+ +++ / +++ / +++ / +++ 4  /  3 3 Quadriparesis with 
predominance in right 
hemibody 
L30 C / C / I / I 3 / 3 / 2 / 2 1+ / 0 / 1+ / 1 ++ / ++ / ++ / ++ 3  /  2 4 Quadriparesis with 
predominance in right 
hemibody 
L31 C / C / I / I 3 / 4 / 3 / 4 0 / 0 / 0 / 0 +++ / ++ / +++ / ++ 2  /  1 1 Right hemiparesis 
L32 I / I / I / I 3 / 2 / 1 / 1 1 / 1+ / 1+ / 3 +++ / +++ / +++ / +++ 4  /  4 4 Triparesis (lower extremities 
and upper left limb affected) 
GMFCS:  Gross Motor Function Classification System. MACS: Manual Ability Classification System. ROM: Range of Motion.  
C: Complete. I: Incomplete. N/A: Not Applicable.  
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TABLE 3. Qualitative Magnetic Resonance Imaging 
Group Cerebral Gray Matter 
Lesion 
Cerebral White Matter Lesion Cerebellum Lesion MRI 
Grade 
Perinatal Brain Damage 
Periventricular White Matter Loss PLIC 
Alteration 
CC 
Alteration 
Cyst(s) 
Cortico-
subcortical 
Alteration 
Basal 
Ganglia 
and/or 
Thalamus 
Alteration 
Frontal Parietal Occipital Temporal 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Katona 
(early 
treatment) 
K12 Bilateral 
fronto-
parietal 
cortical 
atrophy 
with left 
predomina
nce and 
right 
frontal 
encephalo
malacia in 
opercular 
region 
Both 
thalamus 
diminished 
Bilateral Bilateral Bilateral None None Hypoplastic Bilateral 
periventricular 
glial scars in 
both frontal 
and parietal 
regions. 
Underdevelopment 
of both cerebellar 
hemispheres 
Severe Cystic PVL / right frontal 
infarction and left fronto-
parietal atrophy 
K13 Right 
fronto-
parietal 
cortical 
atrophy 
Right 
thalamus 
diminished 
Right Bilateral Bilateral Bilateral Right Hypoplastic Right fronto-
parietal 
porencephalic 
Underdevelopment 
of left hemisphere 
Severe Right PVL/periventricular 
hemorrhagic infarction 
K14 Bilateral 
fronto-
parieto-
occipital 
cortical 
atrophy 
with left 
predomina
nce 
None None None None None None Posterior 
third 
diminished 
None Atrophy / loss of 
declive, atrophy of 
simple lobule, 
atrophy of superior 
and inferior 
semilunar lobule 
Severe Bilateral (with left 
predominance) frontal, 
parietal and occipital 
region cortical-subcortical 
infarction 
K15 None Right 
thalamus, 
globus 
pallidus, 
putamen 
and 
caudate 
Right Right None None Right Middle 
third 
diminished 
One cyst that 
spreads from 
the insula to 
the right frontal 
region 
None Moderate Right PLIC infarction 
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K16 None Right 
thalamus, 
globus 
pallidus, 
putamen 
and 
caudate 
Right None Right 
(minimu
m) 
Right Right Hypoplastic Right fronto-
temporal 
porencephalic 
Underdevelopment 
of left hemisphere 
Severe Right periventricular 
hemorrhagic infarction 
(extensive in frontopolar 
and temporal regions) 
K17 Left fronto-
parietal 
encephalo
malacia (in 
inferior 
perirolandi
c region) 
Right 
thalamus, 
globus 
pallidus, 
putamen 
and 
caudate 
Left Left None None Left Body and 
isthmus 
diminished 
One cyst that 
spreads from 
the insula to 
the left fronto-
parietal region 
None Moderate Left inferior perirolandic 
cortex and PLIC infarction 
K18 Bilateral 
parietal 
region 
encephalo
malacia 
with left 
predomina
nce 
None None None None None None None None None Moderate Bilateral (with left 
predominance) parietal 
infarction 
K19 Left fronto-
parietal 
encephalo
malacia 
None None None None None None None None None Moderate Left perirolandic region 
infarction 
K20 Extensive 
lesion in 
right 
hemisphere 
and left 
parieto-
occipital 
encephalo
malacia 
Severe 
lesion of 
right globus 
pallidus, 
putamen, 
caudate 
and 
thalamus 
Right Bilateral Bilateral Right Right Hypoplastic Right parieto-
temporal 
porencephalic 
Underdevelopment 
of both cerebellar 
hemishperes with 
left predominance 
Severe Left parieto-occipital 
infarction and right brain 
hemisphere extensive 
infarction (occlusion of the 
middle cerebral and 
posterior cerebral right 
arteries) 
K21 Left fronto-
parietal 
cortical 
atrophy 
Left globus 
pallidum, 
putamen, 
caudate 
and 
thalamus 
loss 
Left Bilateral Bilateral Left Left Severely 
hypoplastic 
Left fronto-
parieto-
occipito-
temporal 
extensive 
porencephalic 
Underdevelopment 
of right hemisphere 
Severe Left periventricular 
hemorrhagic infarction / 
PVL  
K22 Bilateral 
fronto-
parietal 
Both 
thalamus 
diminished 
Bilateral Bilateral Bilateral Bilateral Bilateral 
with left 
predomina
Hypoplastic Bilateral 
periventricular 
glial scars in 
Underdevelopment 
of both cerebellar 
hemispheres 
Severe Cystic PVL 
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cortical 
atrophy 
nce parieto-
occipital region 
K23 Bilateral 
fronto-
parietal 
cortical 
atrophy 
Both 
thalamus 
diminished 
Bilateral Bilateral Bilateral None Bilateral Hypoplastic Bilateral 
periventricular 
glial scars in 
frontal and 
parietal regions 
None Severe Cystic PVL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Control 
(late 
treatment) 
L24 None Both 
thalamus 
diminished 
Bilateral Bilateral None None Bilateral 
with right 
predomina
nce 
Hypoplastic Bilateral 
periventricular 
glial scars in 
frontal and 
parietal regions 
None Severe Cystic PVL 
L25 Bilateral 
fronto-
parietal 
cortical 
atrophy 
Both 
thalamus 
diminished 
Bilateral Bilateral Bilateral None Bilateral 
with left 
predomina
nce 
Hypoplastic Bilateral 
periventricular 
glial scars in 
frontal, parietal 
and occipital 
regions 
None Severe Cystic PVL 
L26 Bilateral 
fronto-
parieto-
occipital 
cortical 
atrophy 
Both 
thalamus 
diminished 
Bilateral Bilateral Bilateral None Bilateral Hypoplastic Bilateral 
periventricular 
glial scars in 
frontal and 
parietal regions 
Underdevelopment 
of both cerebellar 
hemispheres 
Severe Cystic PVL 
L27 None Light 
diminishing 
in both 
thalamus 
Bilateral Bilateral Bilateral None Slightest 
bilateral 
Diminished Bilateral glial 
scars at right 
radiated crown 
level in frontal 
and parietal 
regions 
None Severe Cystic PVL 
L28 Bilateral 
fronto-
parietal 
cortical 
atrophy 
Both 
thalamus 
diminished 
and both 
lesion and 
diminishing 
in left 
caudate 
Bilateral Bilateral Left None Bilateral 
with left 
predomina
nce 
Hypoplastic Bilateral 
periventricular 
glial scars in 
frontal and 
parietal regions 
Underdevelopment 
of both cerebellar 
hemispheres 
Severe Left periventricular 
hemorrhagic infarction / 
cystic PVL  
L29 Bilateral 
fronto-
parietal 
cortical 
atrophy 
Severe 
lesion in 
left globus 
pallidum, 
putamen, 
caudate 
and 
Bilateral 
with left 
predomi
nance 
Bilateral Bilateral 
with left 
predomi
nance 
Bilateral Bilateral 
with left 
predomina
nce 
Hypoplastic Left frontal 
porencephalic 
and 
periventricular 
glial scars in 
frontal and 
parietal regions 
Hypoplasia of both 
cerebellar 
hemispheres 
Severe Left periventricular 
hemorrhagic infarction / 
cystic PVL  
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thalamus. 
Right side 
diminished. 
L30 Bilateral 
fronto-
parietal 
cortical 
atrophy 
Both 
thalamus 
diminished 
with left 
predomina
nce 
Bilateral Bilateral Bilateral None Bilateral 
with left 
predomina
nce 
Hypoplastic Bilateral (with 
left 
predominance) 
periventricular 
glial scars in 
frontal and 
parietal regions 
Underdevelopment 
of both cerebellar 
hemispheres 
Severe Cystic PVL 
L31 Bilateral 
frontal 
cortical 
atrophy 
None None Left Left None None Hypoplastic Bilateral 
periventricular 
T2 
hyperintensity 
and T1 
hypointensity in 
parietal and 
occipital regions 
None Moderate Non-cystic PVL with left 
predominance 
L32 Bilateral 
fronto-
parieto-
occipito-
temporal 
cortical 
atrophy 
Both 
thalamus 
diminished 
Bilateral Bilateral Bilateral None Bilateral Hypoplastic Bilateral 
periventricular 
glial scars in 
frontal, parietal 
and occipital 
regions 
Underdevelopment 
of both cerebellar 
hemispheres 
Severe Cystic PVL 
CC: Corpus Callosum. MRI: Magnetic Resonance Imaging. PLIC: Posterior Limb of Internal Capsule. PVL: Periventricular Leukomalacia. 
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TABLE 4. Quantitative Magnetic Resonance Imaging 
Group Corpus Callosum 
Volume 
Right Lateral 
Ventricle Volume 
Left Lateral 
Ventricle Volume 
Right PLIC 
Area  
Left PLIC 
Area  
 
 
 
 
 
 
Healthy 
H1 10.1 cm3 6.7 cm3 6.5 cm3 1.2 cm2 1.1 cm2 
H2 10.6 cm3 4.2 cm3 5.4 cm3 1.3 cm2 1.3 cm2 
H3 14.1 cm3 9.7 cm3 9.5 cm3 1.2 cm2 1.3 cm2 
H4 14.7 cm3 6.7 cm3 4.9 cm3 1.3 cm2 1.2 cm2 
H5 11.8 cm3 6.6 cm3 10.8 cm3 1.4 cm2 1.5 cm2 
H6 14.6 cm3 6.5 cm3 10.9 cm3 1.3 cm2 1.4 cm2 
H7 10.3 cm3 7.7 cm3 3.7 cm3 1.5 cm2 1.1 cm2 
H8 12.7 cm3 9.2 cm3 13.2 cm3 1.2 cm2 1.1 cm2 
H9 12.4 cm3 6.7 cm3 7.5 cm3 1.4 cm2 1.2 cm2 
H10 9.8 cm3 4.2 cm3 4.9 cm3 1.2 cm2 1.2 cm2 
H11 13.7 cm3 7.5 cm3 9.5 cm3 1.2 cm2 1.3 cm2 
Mean 12.3 cm3 6.9 cm3 7.9 cm3 1.3 cm2 1.2 cm2 
SD 1.8 cm3 1.7 cm3 3.0 cm3 0.1 cm2 0.1 cm2 
 
 
 
 
 
 
Katona (early 
treatment) 
K12 3.9 cm3 22.7 cm3 16.6 cm3 0.7 cm2 0.7 cm2 
K13 4.9 cm3 85.2 cm3 40.9 cm3 0.1 cm2 1.0 cm2 
K14 9.7 cm3 6.7 cm3 6.3 cm3 1.2 cm2 1.1 cm2 
K15 8.1 cm3 5.9 cm3 5.1 cm3 0.2 cm2 1.0 cm2 
K16 4.0 cm3 33.1 cm3 7.8 cm3 0.9 cm2 0.9 cm2 
K17 8.7 cm3 4.9 cm3 6.4 cm3 1.3 cm2 0.1 cm2 
K18 10.6 cm3 4.3 cm3 4.3 cm3 1.2 cm2 1.0 cm2 
K19 12.2 cm3 6.4 cm3 7.9 cm3 1.0 cm2 1.0 cm2 
K20 3.3 cm3 139.9 cm3 9.2 cm3 0.4 cm2 0.9 cm2 
K21 0.2 cm3 23.3 cm3 240.5 cm3 N/A N/A 
K22 9.0 cm3 62.9 cm3 81.1 cm3 1.3 cm2 1.3 cm2 
K23 3.6 cm3 21.0 cm3 26.0 cm3 0.6 cm2 0.8 cm2 
Mean 6.5 cm3 34.7 cm3 37.7 cm3 0.8 cm2 0.9 cm2 
SD 3.6 cm3 41.6 cm3 67.6 cm3 0.4 cm2 0.2 cm2 
 
 
 
 
Control (late 
treatment) 
L24 6.7 cm3 14.9 cm3 18.5 cm3 0.8 cm2 1.1 cm2 
L25 5.7 cm3 11.9 cm3 13.1 cm3 1.2 cm2 1.3 cm2 
L26 5.6 cm3 26.7 cm3 26.8 cm3 0.9 cm2 1.0 cm2 
L27 11.1 cm3 35.5 cm3 56.0 cm3 1.1 cm2 1.1 cm2 
L28 8.0 cm3 27.6 cm3 31.5 cm3 0.8 cm2 1.2 cm2 
L29 5.4 cm3 37.1 cm3 60.2 cm3 0.8 cm2 0.3 cm2 
L30 7.7 cm3 22.3 cm3 30.4 cm3 1.0 cm2 1.1 cm2 
L31 5.2 cm3 7.5 cm3 10.6 cm3 0.9 cm2 0.9 cm2 
L32 5.2 cm3 20.1 cm3 19.0 cm3 0.5 cm2 0.6 cm2 
Mean 6.7 cm3 22.6 cm3 29.6 cm3 0.9 cm2 0.9 cm2 
SD 1.9 cm3 10.1 cm3 17.7 cm3 0.1 cm2 0.3 cm2 
PLIC: Posterior Limb of Internal Capsule. N/A: Not Available. 
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Confusion matrix for clustering results based on three classes (C1 for Healthy group, C2 for early treated group with 
Katona therapy and C3 for late treated group without Katona therapy) of three databases: quantitative magnetic 
resonance imaging (a), motor evoked potentials (b) and neuropediatric evaluation / motor performance tests (c). The 
color green is related to healthy participants, yellow to patients (with and without Katona therapy) and red with 
misclassification. 
TABLE 5. Confusion Matrix for Clustering Results. 
a) Quantitative Magnetic Resonance Imaging 
  
Healthy Patient 
  
 
  C1 C2 C3 
  
H
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lt
h
y 
C1 11 0 0 11 
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C
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ss
 
P
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t C2 0 5 7 12 
C3 0 3 6 9 
  
11 8 13 
  
  
Output Class 
 
  
b) Motor Evoked Potentials 
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20 10 2 
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c) Neuropediatric Evaluation 
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  C1 C2 C3 
  
H
ea
lt
h
y 
C1 11 0 0 11 
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C3 0 4 5 9 
  
19 7 6 
  
  
Output Class 
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FIGURES 
 
 
 
Fig. 1. Magnetic resonance imaging of perinatal brain damage. A) Arterial ischemic stroke. 
B) Cystic periventricular leukomalacia (PVL). C) Periventricular hemorrhagic infarction 
and cystic PVL. D) Cystic PVL. E) Neuroradiological findings compatible with non-cystic 
PVL. F) Cystic PVL and left frontal porencephalic cyst secondary to periventricular 
hemorrhagic infarction. Images in radiological convention.  
R: Right. L: Left. 
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Fig. 2. Volumetric magnetic resonance imaging. 3D reconstruction of the corpus callosum and lateral ventricles with corresponding 
volumetric measurement and sagittal T1-weighted and axial T2-weighted sequences with overlaying volumetric reconstruction. A) 
Healthy child at 9 years old. B) Patient of the Katona group (early treated) at 11 years old. C) Patient of the Control group (late treated) 
at 10 years old. 
A: Anterior. P: Posterior. R: Right. L: Left. 
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SUPPLEMENTARY MATERIAL 
MAGNETIC RESONANCE IMAGING PARAMETERS 
Brain magnetic resonance imaging (MRI) studies in infancy stage with early perinatal brain 
damage (PBD) detection aim were only for the Katona group (only group with early 
diagnosis and longitudinal follow-up) and were acquired with a 1.0 Tesla MRI scanner 
(Philips Medical Systems, Best, Netherlands). Infant brains were scanned during natural 
sleep and used ear protection. Structural images included: axial and sagittal T1-weighted 
conventional spin echo (SE), repetition time (TR) = 405 ms, echo time (TE) = 15 ms, flip 
angle 62°, slices 15, slice thickness 5 mm, matrix 256 x 166, field of view (FoV) = 220 x 
220 mm, voxel sizes of 6.0 x 0.8 x 0.8 mm3. Axial and coronal T2-weighted SE, TR/TE 
2600/150 ms, flip angle 90°, slices 30, slice thickness 6 mm, matrix 256 x 153, FoV 200 x 
200 mm2, voxel sizes of 0.8 x 6.6 x 0.8 mm3. 
Brain MRI studies for all participants in a range 7-to-16 years (transversal analysis) were 
acquired with a 3.0 Tesla scanner (General Electric Healthcare, Milwaukee, Wisconsin, 
US). A 16-channel neurovascular head coil (HDNV) was used for data acquisition. All 
participants were awake and used ear protection. Structural images included: coronal 3D 
T1-weigthed SPGR, TR/TE 6/2 ms, flip angle 12°, slices 392, slice thickness 1 mm, matrix 
224 x 224, FoV 220 x 220 mm2, voxel sizes of 0.8 x 0.5 x 0.8 mm3. Coronal 3D T2-
weigthed SE, TR/TE 2500/68 ms, flip angle 90°, slices 196, slice thickness 1 mm, matrix 
224 x 224, FoV 220 x 220 mm2, voxel sizes of 0.8 x 1.0 x 0.8 mm3. Axial T2-weigthed 
FSE, TR/TE 7000/100 ms, flip angle 111°, slices 70, slice thickness 2 mm, matrix 448 x 
352, FoV 220 x 220 mm2, voxel sizes of 0.4 x 0.4 x 2.0 mm3. Axial 3D-TOF SPGR, TR/TE 
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20/3 ms, flip angle 15°, slices 120, slice thickness 1.2 mm, matrix 352 x 192, FoV 180 x 
180 mm2, voxel sizes of 0.3 x 0.3 x 0.6 mm3. Diffusion tensor spin echo, single-shot EPI, 
TR/TE 8000/100 ms, flip angle 90°, slices 50, slice thickness 2 mm, matrix 128 x 128, FoV 
220 x 220 mm2, voxel sizes of 0.8 x 0.8 x 2.0 mm3. We obtained diffusion-weighted images 
along 64 different directions with a b-value of 2000 s/mm2, and 2 non-diffusion-weighted 
images (b = 0 s/mm2). Time acquisition for these 5 sequences was approximately 22 min. 
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METHODOLOGY FOR THE QUANTITATIVE MAGNETIC RESONANCE 
IMAGING ANALYSIS 
Volumetric analysis 
Volumetric analysis of the corpus callosum and lateral ventricles was performed from 
coronal 3D T1-weighted SPGR sequence. The T1-weighted sequence allows a better 
observation between the white matter and gray matter contrast, favoring the manual 
segmentation of the corpus callosum. The manual segmentation, quantitative analysis and 
3D models visualization were performed with 3D slicer v4.10.2 software. 
 
1. Manual segmentation  
1.1 Initial inspection and image orientation for segmentation  
The anatomical boundaries and morphological details are not easily determined in a single 
plane. Sometimes the visualization only in one plane (e.g., sagittal for corpus callosum) is 
not enough to determine the anatomical limits. It is necessary to visualize the three planes 
(sagittal, axial and coronal) to endorse an adequate marking and an optimal visualization of 
the lateral, superior, inferior, anterior and posterior limits. Therefore, visual evaluation of 
the sagittal, coronal and axial plane is made to determine the anatomical boundaries of the 
corpus callosum and lateral ventricles and/or to be able to detect any anatomical 
abnormality that may interfere with the final volumetry. Afterwards, the operator positions 
itself systematically in a specific plane to initiate the segmentation process. The initial 
orientation of the corpus callosum is determined in the sagittal plane (at the anterior 
commissure – posterior commissure line level), whereas the initial orientation of the lateral 
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ventricles is determined by the axial plane at the ventricular dome height (at superior 
corona radiata level). 
1.2 Manual segmentation direction  
The corpus callosum segmentation is made in the sagittal plane in a bilateral parasagittal 
direction using as a secondary anatomical reference the axial plane. For the lateral 
ventricles’ segmentation, the axial plane is used with a cranial-caudal direction and with the 
sagittal and coronal planes as secondary anatomical reference.   
 
2. Anatomical boundaries 
2.1 Corpus callosum  
The anatomical boundaries of the corpus callosum are not clear in the parasagittal plane. In 
general terms, conventional magnetic resonance imaging (MRI) don’t allow differentiation 
of the fascicles. Consequently, the lateral portions of the corpus callosum are determined in 
the axial plane to corroborate that the corpus callosum is not being overestimated when the 
cingulum is included in planes where the corpus callosum limits are undistinguishable 
(parasagittal). The information that the axial plane gives is fundamental for delimiting the 
lateral anatomical boundaries of the corpus callosum. The anatomical point of reference in 
the axial plane at the genu level is the caudate head and the cortex of the cingulum gyrus (at 
frontal lobe level). The anatomical point of reference at the splenium level in the axial 
plane is the gyrus of the cingulum (at parietal level) and the lateral portion of the choroid 
plexus of the lateral ventricles. The superior, inferior, anterior and posterior anatomical 
boundaries of the corpus callosum are clear in the sagittal plane thanks to the contrast 
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between white and gray matter of the T1- weighted. These anatomical boundaries are given 
by the marginal callous fissure and cingulum gyrus. Systematically, the corpus callosum is 
segmented including the genu, body, isthmus and splenium (not including the tapetum). 
 
 
 
 
 
 
 
 
 
 
 
 
2.2 Lateral ventricles 
The anatomical boundaries of the lateral ventricles are clear despite its morphological 
variability in pediatric stage. The manual segmentation of the lateral ventricles includes the 
frontal horn, the body of lateral ventricle and occipital and temporal horn. The lateral 
anatomical boundaries in dorsal-ventral direction are the caudate nucleus and thalamus at 
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the ventricular dome / body level, and corresponding periventricular white matter. The 
medial boundaries in cranial-caudal direction are the septum pellucidum, columns (anterior 
pillars) and body of the fornix, interventricular foramina of Monro and the crura of the 
fornix (posterior pillars), and the hippocampus at temporal level. Any structural condition 
or lesion with loss of periventricular white matter that communicates widely with the lateral 
ventricle was measured and quantified as part of the lateral ventricle (e.g., porencephalic 
cyst as a consequence of periventricular hemorrhagic infarction). 
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Area of the posterior limb of internal capsule  
The areas of the posterior limb of internal capsule were calculated in RGB-color maps 
(color by orientation mode) from diffusion weighted imaging dataset. The RGB-color maps 
allows us to distinguish the major fibers / pathways of white matter and it is extremely 
helpful to determine the portions of the internal capsule (e.g., anterior limb can be observed 
in green color; posterior limb can be observed in blue color). The hand-drawn of regions of 
interest (ROIs) were performed systematically in posterior limb of internal capsule (in blue 
color) in axial plane at the level of the basal ganglia. The image processing, ROIs drawings 
and areas calculations were performed in 3D slicer v4.10.2 software. 
 
 
 
 
 
 
 
 
 
